{"preliminary_commentary":{"by_channel":{"x_thread":4},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["ociperlimab","tislelizumab"]],"indication":"untreated PD-L1-selected locally advanced, unresectable or metastatic NSCLC","name":"AdvanTIG-302","nct_id":"NCT04746924","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=advantig-302-nct04746924. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants received ociperlimab 900 mg and tislelizumab 200 mg intravenously every 3 weeks. Treatment continued until lack of benefit, unacceptable toxicity, or withdrawal for other reasons.","label":"Arm A: Ociperlimab plus Tislelizumab","type":"EXPERIMENTAL"},{"description":"Participants received pembrolizumab 200 mg and placebo intravenously every 3 weeks. Treatment continued until lack of benefit, unacceptable toxicity, or withdrawal for other reasons.","label":"Arm B: Pembrolizumab plus Placebo","type":"ACTIVE_COMPARATOR"},{"description":"Participants received tislelizumab 200 mg and placebo intravenously every 3 weeks. Treatment continued until lack of benefit, unacceptable toxicity, or withdrawal for other reasons.","label":"Arm C: Tislelizumab plus Placebo","type":"PLACEBO_COMPARATOR"},{"description":"Japanese participants received ociperlimab 900 mg and tislelizumab 200 mg every 3 weeks. Treatment continued until lack of benefit, unacceptable toxicity, or withdrawal for other reasons.","label":"Safety Run-In Substudy","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2026-03-18","type":"ACTUAL"},"conditions":["Non-small Cell Lung Cancer","NSCLC"],"enrollment":{"count":669,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Tislelizumab","otherNames":["BGB-A317"],"type":"DRUG"},{"name":"Ociperlimab","otherNames":["BGB-A1217"],"type":"DRUG"},{"name":"Pembrolizumab","otherNames":["KEYTRUDA"],"type":"DRUG"},{"name":"Placebo","otherNames":[],"type":"DRUG"}],"last_update":"2026-05-12","lead_sponsor":"BeiGene","official_title":"A Phase 3, Randomized, Double-Blind Study of Ociperlimab, an Anti-TIGIT Antibody, in Combination With Tislelizumab Compared to Pembrolizumab in Patients With Previously Untreated, PD-L1-Selected, and Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer","overall_status":"TERMINATED","phases":["PHASE3"],"primary_completion_date":{"date":"2025-05-30","type":"ACTUAL"},"primary_outcomes":[{"measure":"Overall Survival (OS) in Arms A and B","timeFrame":"From randomization until the end of the study. Maximum time on study was 45.0 months"},{"measure":"Safety Run-In Substudy: Number of Participants Experiencing Adverse Events (AEs)","timeFrame":"From first dose of study drug to 30 days after last dose. Maximum treatment duration was 12.45 months."},{"measure":"Safety Run-In Substudy: Serum Concentration of Ociperlimab","timeFrame":"Cycle 1 Day 1 (C1D1) Postdose (30 minutes after end of infusion), 24 and 72 Hours Postdose; C1D8; C1D15; C2D1 Predose and Postdose; C5D1 Predose; C5D1 Postdose; C5D8; C5D15; C6D1 Predose and Postdose; C9D1 Predose; C13D1 Predose; End of Treatment."}],"references":[{"citation":"Socinski MA, Reck M, Paz-Ares L, Nishio M, Spira AI, Yu X, Melkadze T, Zeng A, Martinez-Bueno A, Li X, Arulananda S, Zuo Y, Chica-Duque S, Dai W, Zhou J, Tan W, Lu S. AdvanTIG-302: Phase 3 Study of Ociperlimab (Anti-TIGIT) + Tislelizumab (Anti-PD-1) Versus Pembrolizumab in Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer With PD-L1 >/=50. J Thorac Oncol. 2026 Jul 14:104089. doi: 10.1016/j.jtho.2026.104089. Online ahead of print.","pmid":"42448175","type":"DERIVED"}],"start_date":{"date":"2021-05-24","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer","url":"https://clinicaltrials.gov/study/NCT04746924"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/advantig-302-nct04746924"}